[1] Qi L, Zhang Q, Miao Y, et al.Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development[J]. Int J Cancer, 2020, 146(5): 1421-1434. [2] Kienzl M, Hasenoehrl C, Valadez-Cosmes P, et al.IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils[J]. Oncoimmunology, 2020, 9(1): 1776059. [3] Xu L, Zheng Y, Wang J, et al.IL-33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice[J]. Biotechnol Lett, 2020, 42(7): 1113-1121. [4] Ochayon D E, Ali A, Alarcon P C, et al.IL-33 promotes type 1 cytokine expression via p38 MAPK in human NK cells[J]. J Leukoc Biol, 2020, 107(4): 663-671. [5] Jin Z, Lei L, Lin D, et al.IL-33 released in the liver inhibits tumor growth via promotion of CD4(+) and CD8(+) T cell responses in hepatocellular carcinoma[J]. J Immunol, 2018, 201(12): 3770-3779. [6] Eissmann M F, Dijkstra C, Wouters M A, et al.Interleukin 33 signaling restrains sporadic colon cancer in an interferon-gamma-dependent manner[J]. Cancer Immunol Res, 2018, 6(4): 409-421. [7] Lucarini V, Ziccheddu G, Macchia I, et al.IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils[J]. Oncoimmunology, 2017, 6(6): e1317420. [8] Sinsimer K S, Gratacos F M, Knapinska A M, et al.Chaperone Hsp27, a novel subunit of AUF1 protein complexes, functions in AU-rich element-mediated mRNA decay[J]. Mol Cell Biol, 2008, 28(17): 5223-5237. [9] Li M L, Defren J, Brewer G.Hsp27 and F-box protein beta-TrCP promote degradation of mRNA decay factor AUF1[J]. Mol Cell Biol, 2013, 33(11): 2315-2326. [10] Knapinska A M, Gratacos F M, Krause C D, et al.Chaperone Hsp27 modulates AUF1 proteolysis and AU-rich element-mediated mRNA degradation[J]. Mol Cell Biol, 2011, 31(7): 1419-1431. [11] J Guhaniyogi G B. Regulation of mRNA stability in mammalian cells[J]. Gene, 2001, 265(1-2): 11-23. [12] Davila D, Jimenez-Mateos E M, Mooney C M, et al. Hsp27 binding to the 3'UTR of bim mRNA prevents neuronal death during oxidative stress-induced injury: a novel cytoprotective mechanism[J]. Mol Biol Cell, 2014, 25(21): 3413-3423. [13] Gong P J, Shao Y C, Huang S R, et al.Hypoxia-associated prognostic markers and competing endogenous RNA co-expression networks in breast cancer[J]. Front Oncol, 2020, 10:579868. [14] Liew F Y, Girard J P, Turnquist H R.Interleukin-33 in health and disease[J]. Nat Rev Immunol, 2016, 16(11): 676-689. [15] Milovanovic M, Volarevic V, Radosavljevic G, et al.IL-33/ST2 axis in inflammation and immunopathology[J]. Immunol Res, 2012, 52(1-2): 89-99. [16] Baumann C, Bonilla W V, Frohlich A, et al.T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses[J]. Proc Natl Acad Sci U S A, 2015, 112(13): 4056-4061. [17] Komai-Koma M, Wang E, Kurowska-Stolarska M, et al.Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12[J]. Immunobiology, 2016, 221(3): 412-417. [18] Lusty E, Poznanski S M, Kwofie K, et al.IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-gamma production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation[J]. Mol Immunol, 2017, 88:138-147. [19] Mccarthy P C, Phair I R, Greger C, et al.IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2/3[J]. Immunol Cell Biol, 2019, 97(1): 54-71. [20] Laroia G, Cuesta R, Brewer G, et al.Control of mRNA decay by heat shock-ubiquitin-proteasome pathway[J]. Science, 1999, 284(5413): 499-502. [21] Mavropoulos A, Sully G, Cope A P, et al.Stabilization of IFN-gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells[J]. Blood, 2005, 105(1): 282-288. |